If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Todd Schell's research focuses on defining immune-based therapies for cancer. His interests include evaluating approaches to improve the persistence and function of tumor-reactive T lymphocytes within the tumor microenvironment. These studies have defined how tumor-reactive T-cells behave in distinct types of cancer including those that occur in the brain, pancreas, prostate and skin. Emphasis is placed on the use of adoptive T-cell therapies as well as defining how existing immune-based therapies currently used in cancer patients can be further improved.

Recent studies from the Schell laboratory highlight how antibody-based therapies targeting CD40 or PD-1 can be improved through combination with existing approaches such as radiation or common medications such as beta-blockers. Through collaborations with clinical investigators, translational studies focus on identification of patient characteristics that are associated with durable clinical responses to immune-based therapies, particularly for metastatic melanoma.

In addition to his research, Dr. Schell is the faculty director of Penn State College of Medicine's Flow Cytometry Core Facility.

Education/Academic qualification

Postdoctoral Training, Penn State College of Medicine

… → 1999

PhD, West Viginia University School of Medicine

… → 1995

Fingerprint Dive into the research topics where Todd Schell is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • BIOLOGY OF SV40-SPECIFIC TRANSPLANTATION ANTIGEN

    Schell, T. & Tevethia, S. S.

    National Institutes of Health

    6/1/7811/30/15

    Project: Research project

  • Research Output

    • 1478 Citations
    • 22 h-Index
    • 65 Article
    • 3 Review article
    • 2 Comment/debate
    • 1 Letter
    Open Access
  • Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer

    Bazewicz, C. G., Dinavahi, S. S., Schell, T. D. & Robertson, G. P., Jan 2019, In : Immunology. 156, 1, p. 47-55 9 p.

    Research output: Contribution to journalReview article

  • 7 Scopus citations
    Open Access
  • 3 Scopus citations

    Increased circulating microparticles in streptozotocin-induced diabetes propagate inflammation contributing to microvascular dysfunction

    Feng, Q., Stork, C. J., Xu, S., Yuan, D., Xia, X., LaPenna, K. B., Guo, G., Sun, H., Xu, L. C., Siedlecki, C. A., Brundage, K. M., Sheaffer, N., Schell, T. D. & He, P., Feb 1 2019, In : Journal of Physiology. 597, 3, p. 781-798 18 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity

    Kokolus, K. M., Haley, J. S., Koubek, E. J., Gowda, R., Dinavahi, S. S., Sharma, A., Claxton, D. F., Helm, K. F., Drabick, J. J., Robertson, G. P., Neighbors, J. D., Hohl, R. J. & Schell, T. D., Feb 1 2019, In : OncoImmunology. 8, 2, e1539614.

    Research output: Contribution to journalArticle